How should ropinirole (Requip) be initiated and titrated for restless legs syndrome, and what are the key side effects and monitoring considerations?

Ropinirole (Requip) for Restless Legs Syndrome

The 2025 American Academy of Sleep Medicine guidelines now recommend AGAINST the standard use of ropinirole for RLS due to the significant risk of augmentation with long-term use, despite its short-term efficacy. 1

Current Guideline Position

The AASM suggests against the standard use of ropinirole (conditional recommendation, moderate certainty of evidence), marking a significant shift from previous practice. 1 The guideline explicitly states that ropinirole may only be used in patients who place a higher value on short-term symptom reduction and a lower value on long-term adverse effects, particularly augmentation. 1

Preferred First-Line Alternatives

The 2025 guidelines now strongly recommend the following as first-line agents instead:

• Gabapentin enacarbil (strong recommendation, moderate certainty)
• Gabapentin (strong recommendation, moderate certainty)
• Pregabalin (strong recommendation, moderate certainty)
• IV ferric carboxymaltose in patients with appropriate iron status (strong recommendation, moderate certainty) 1

If Ropinirole Is Still Prescribed

Dosing and Titration

According to FDA labeling, if ropinirole is used despite guideline recommendations 2:

Initial dosing:

• Start at 0.25 mg once daily, taken 1-3 hours before bedtime
• Can be taken with or without food

Titration schedule:

• Increase gradually based on symptom response and tolerability
• Maximum recommended dose: 4 mg daily

Special population - Renal impairment:

• In end-stage renal disease on hemodialysis: maximum dose 3 mg/day 2

Critical Side Effects and Monitoring

Augmentation (Most Important Long-Term Complication):

• This is the primary reason for the guideline downgrade
• Symptoms worsen over time, occurring earlier in the day, with greater intensity, and spreading to other body parts
• More common with dopaminergic agents than α2δ ligands (gabapentin/pregabalin) 3
• Requires special monitoring throughout treatment 3

Somnolence and Sleep Attacks:

• Patients may fall asleep during activities of daily living without warning 2
• Occurs even without pre-existing somnolence
• Before initiating: Directly question about drowsiness, assess for concomitant sedating medications, alcohol use, sleep disorders, and drugs that increase ropinirole levels (e.g., ciprofloxacin) 2
• If significant daytime sleepiness develops: Ordinarily discontinue ropinirole; advise patients not to drive 2

Orthostatic Hypotension/Syncope:

• Syncope reported in 1% of RLS patients vs 0.2% with placebo 2
• Orthostatic hypotension in 0.8% vs 0.4% with placebo in 12-week trials 2
• In forced-titration studies: 25% experienced hypotension/orthostatic hypotension vs 0% with placebo 2
• Monitor blood pressure during dose escalation, especially after standing from lying/seated position 2
• Most cases occur >4 weeks after initiation, typically with recent dose increases 2
• Can trigger prescribing cascades in elderly patients 4

Gastrointestinal Effects:

• Nausea: 37.2% with ropinirole vs 9.4% with placebo (p<0.0001) 5
• Vomiting: 10.9% vs 2.6% with placebo (p<0.0001) 5
• These represent nearly 50% of all adverse events 5
• Generally mild-to-moderate but can be treatment-limiting 6

Key Clinical Pitfalls

1. Avoid in patients requiring long-term therapy: The augmentation risk makes ropinirole unsuitable for chronic management, which most RLS patients require

2. Do not use as first-line: Start with gabapentin enacarbil, gabapentin, or pregabalin per current guidelines 1

3. Check iron status first: Evaluate ferritin and transferrin saturation before any pharmacotherapy; IV iron may be appropriate 1

4. Elderly patients are high-risk: More susceptible to orthostatic hypotension and falls 4

5. Retitration required after interruption: If therapy is stopped and restarted, retitrate from the beginning 2

6. Drug interactions: CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) increase ropinirole levels and side effect risk 2

When to Consider Discontinuation

• Development of augmentation symptoms
• Significant daytime sleepiness or sleep attacks during active tasks
• Recurrent syncope or symptomatic orthostatic hypotension
• Intolerable nausea/vomiting despite dose adjustment
• Need for long-term therapy (switch to α2δ ligands)

Evidence Quality Note

The 2025 AASM guideline represents the highest quality, most recent evidence and should guide practice. 1 While older studies from 2004-2006 demonstrated short-term efficacy 7, 8, 9, the long-term augmentation risk identified in subsequent research 3 has fundamentally changed the risk-benefit calculation, leading to the current recommendation against standard use.